Is Breast Cancer Hereditary?

mutations in genes such as BRCA1, BRCA2, PALB2, TP53 and CHEK2. The remaining 90 to 95 percent of cases are sporadic, caused by genetic damage acquired over a lifetime. A strong family history of breast, ovarian or prostate cancer is the clearest pointer towards inherited risk and the trigger for genetic testing.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in Bangalore, India, “Most women I see worry about family history more than they need to. True hereditary breast cancer is uncommon, but when it’s there, knowing about it changes everything, from the age screening starts to whether preventive surgery is on the table.“

A handful of genes account for most inherited cases, with risk levels that vary by mutation type.

• BRCA1: A BRCA1 mutation carries a 55 to 70 percent lifetime breast cancer risk and a 40 percent ovarian cancer risk, with cancers often appearing before age 50 and frequently presenting as triple-negative disease.
• BRCA2: BRCA2 mutations carry a similar 45 to 70 percent lifetime breast cancer risk, with a stronger link to male breast cancer, prostate cancer and pancreatic cancer in affected families.
• PALB2: PALB2 sits alongside BRCA2 in the DNA repair pathway and carries a 35 to 60 percent lifetime risk, making it the third most clinically important breast cancer gene after BRCA1 and BRCA2.
• Others:TP53, CHEK2, ATM and CDH1 mutations each carry moderate to high risk and are picked up through panel testing, particularly when families show early-onset cancers across multiple sites and need detailed diagnosis and staging workup.

A clear pattern across two or more close relatives, especially before age 50, is what usually triggers formal genetic counselling.

Once a mutation is confirmed, management shifts towards earlier surveillance, prevention and informed surgical decisions.

• Screenin: Women with BRCA1 or BRCA2 mutations start mammography and breast MRI from age 25 to 30, ten years earlier than average-risk women, with annual imaging that often alternates between modalities.
• Lifestyle: Maintaining a healthy weight, limiting alcohol, regular exercise and avoiding long-term hormone replacement therapy reduce overall risk in mutation carriers, even if they don’t eliminate it.
• Medication: Tamoxifen and raloxifene reduce breast cancer risk by around 40 to 50 percent in high-risk women, and discussion of these options forms part of standard genetic counselling for confirmed carriers.
• Surgery: Risk-reducing mastectomy lowers breast cancer risk by over 90 percent in mutation carriers, and removal of the ovaries before menopause further reduces both breast and ovarian cancer risk through shared precision oncology protocols.

The right pathway depends on age, mutation type and personal preference, and our blog on early detection covers why structured surveillance matters as much as the genetic result itself.

Dr. Sandeep Nayak brings over 20 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery, an MRCS from the UK and a fellowship in Laparoscopic and Robotic Surgical Oncology to breast cancer care at KIMS Hospital, Bangalore. He’s the recipient of the K Subhramanyam Robotic Innovation Award 2023 and serves as Executive Director of Surgical Oncology and Robotic Surgery, with originator credits for advanced minimally invasive techniques and over 25 published clinical studies.

Women with a family history or confirmed mutations are guided through genetic counselling, structured surveillance and risk-reducing options ranging from surveillance imaging to preventive surgery and oncoplastic reconstruction. Each plan reflects individual risk, not a generic protocol. Call +91 8035740000 to book your consultation.

Reference

Reference

1. National Cancer Institute — Breast Cancer Symptoms
2. World Health Organization — Breast Cancer Fact Sheet

Disclaimer: The information shared in this content is for educational purposes and not for promotional use.